Showing 2201-2210 of 3315 results for "".
- Alcon Introduces New AIR OPTIX Plus HydraGlyde Multifocal Contact Lenseshttps://modernod.com/news/alcon-introduces-new-air-optix-plus-hydraglyde-multifocal-contact-lenses/2479894/Alcon is expanding its multifocal portfolio with the launch of AIR OPTIX plus HydraGlyde multifocal contact lenses. As with Alcon’s other multifocal portfolio contact lens options – including DAILIES TOTAL1, DAILIES AquaComfort Plus, and AIR OPTIX AQUA – this latest innovation offers presbyopic p
- Contact Lens Companies Seek Summary Judgment in Lawsuit Over Minimum Pricinghttps://modernod.com/news/contact-lens-companies-seek-summary-judgment-in-lawsuit-over-minimum-pricing/2479910/Three contact lens companies and a distributor, who are defendants in a class-action lawsuit over pricing, filed a motion seeking a summary judgment in the matter in U.S. District Court for the Middle District of Florida here earlier this week, according to a
- Lenstec Completes Enrollment of FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-enrollment-of-fda-trial-for-sbl-3-iol/2479919/Lenstec announced that it has completed enrollment of the FDA trial for the SBL-3 IOL. The Lenstec SBL-3 IOL (segmented bifocal lens) is a non-concentric asymmetric multifocal refractive IOL that provides patients with superior near, intermediate, and distance vision. It also improves contrast se
- A Contact Lens Was Embedded in Woman’s Eyelid for 28 Yearshttps://modernod.com/news/a-contact-lens-was-embedded-in-womans-eyelid-for-28-years/2479936/Imagine going to the eye doctor because your upper eyelid is swollen and painful. The doctor tells you it’s a cyst and operates. Inside the blister, the surgeon finds a contact lens: a rigid gas-permeable one.
- ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-on-qr-110-for-lebers-congenital-amaurosis-10/2479967/ProQR Therapeutics announced the publication of a peer-reviewed manuscript describing the preclinical validation for the use of QR-110 in the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal
- Glaucoma Research Foundation Grant Leads to Breakthrough in Neuron Regenerationhttps://modernod.com/news/glaucoma-research-foundation-grant-leads-to-breakthrough-in-neuron-regeneration/2479971/The Glaucoma Research Foundation announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at the University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also
- Eton Pharma Reports Positive Topline Results from Phase 3 Trial of EM-100https://modernod.com/news/eton-pharma-reports-positive-topline-results-from-phase-3-trial-of-em-100/2479990/Eton Pharmaceuticals announced positive topline results for its phase 3 study of EM-100 ophthalmic solution. If approved, EM-100 would be the first topical, preservative-free formulation
- Heidelberg Engineering Announces Leadership Changeshttps://modernod.com/news/heidelberg-engineering-announces-leadership-changes/2480004/Heidelberg Engineering announced changes to the leadership team. Ali Tafreshi who has served in sales, marketing and research capacities in both the United States and German organizations
- LensGen Announces Funding And Patent Successhttps://modernod.com/news/lensgen-announces-funding-and-patent-success/2480017/LensGen, a private California company developing the world’s first modular, fluid-optic, curvature changing IOL, is reporting significant progress in its effort to transform how presbyopia is addressed, according to a company news release. The company successfully achieved a key clin
- Bausch + Lomb Announces FDA Filing Acceptance for Loteprednol Etabonate Ophthalmic Gelhttps://modernod.com/news/bausch-lomb-announces-fda-filing-acceptance-for-loteprednol-etabonate-ophthalmic-gel/2480037/Bausch + Lomb announced that the FDA has accepted the new drug application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel 0.38%. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2019. If approved, the product would be the lowest concentrated lote